MORRISTOWN, N.J.--(BUSINESS WIRE)--Alitair Pharmaceuticals, Inc., an early stage pharmaceutical company with multiple respiratory product candidates in development, today announced that it has retained Finn, Warnke & Gayton, LLP (“FWG”), to sell two Alitair patents and an associated royalty stream at a sealed bid sale on May 24, 2013. The first patent was issued in 2012 and covers the use of ion exchange resins in immediate-release and extended-release solid oral dosage forms. The second patent was issued in 2013 and covers the use of ion exchange resins in immediate-release and extended-release oral solid formulations of benzonatate, a non-narcotic prescription cough product. The royalty stream includes milestone payments and has an estimated net present value of $7.5 million.
